Physician profile
Mark Allen Orourke
NPI 1750386058
$1,009.15
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $270 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $233.65 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $145.36 | 2020 | |
| Incyte Corporation | $125.01 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $109.79 | 2019 | |
| Amgen INC. | $109.26 | 2019 | |
| Merck Sharp & Dohme LLC | $108.81 | 2019 | |
| Kite Pharma, INC. | $94.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $71.09 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Orourke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.